| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 9.6% | $11,974,668 | 14,772,598 | ORBIMED ADVISORS LLC | 08 Oct 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 9.9% | $6,208,827 | 8,223,612 | TANG CAPITAL MANAGEMENT, LLC | 31 Mar 2025 |
As of 31 Dec 2025, 1 institutional investors reported holding 60,511 shares of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET). This represents 0.04% of the company’s total 153,881,229 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 60,511 | $509,503 | -$48,448,503 | $8.42 | 1 |
| 2025 Q3 | 51,335,037 | $41,591,047 | -$36,555 | $0.81 | 53 |
| 2025 Q2 | 51,603,071 | $31,484,026 | -$3,114,221 | $0.61 | 47 |
| 2025 Q1 | 55,856,035 | $42,041,103 | -$1,434,569 | $0.76 | 56 |
| 2024 Q4 | 57,616,208 | $55,430,722 | -$613,083 | $0.96 | 61 |
| 2024 Q3 | 57,126,257 | $82,259,457 | -$8,520,911 | $1.44 | 62 |
| 2024 Q2 | 63,950,445 | $77,407,916 | -$23,984,627 | $1.21 | 83 |
| 2024 Q1 | 75,135,656 | $176,537,613 | +$98,192,610 | $2.35 | 96 |
| 2023 Q4 | 33,363,531 | $63,033,300 | -$3,182,870 | $1.89 | 76 |
| 2023 Q3 | 35,675,697 | $48,851,768 | -$4,181,891 | $1.37 | 83 |
| 2023 Q2 | 37,121,626 | $90,180,708 | -$28,161,740 | $2.43 | 92 |
| 2023 Q1 | 40,249,929 | $231,250,449 | -$1,583,181 | $5.76 | 105 |
| 2022 Q4 | 42,143,638 | $376,757,638 | -$18,208,642 | $8.94 | 100 |
| 2022 Q3 | 41,668,911 | $592,464,001 | +$53,381,880 | $14.22 | 98 |
| 2022 Q2 | 37,871,013 | $553,032,820 | +$48,530,334 | $14.60 | 97 |
| 2022 Q1 | 33,013,038 | $659,188,374 | +$43,094,111 | $19.97 | 82 |
| 2021 Q4 | 30,385,666 | $531,158,057 | +$190,514,360 | $17.49 | 78 |
| 2021 Q3 | 19,920,035 | $156,119,000 | -$14,652,181 | $7.84 | 54 |
| 2021 Q2 | 21,191,598 | $218,012,000 | +$7,951,899 | $10.29 | 60 |
| 2021 Q1 | 20,347,324 | $265,987,000 | +$141,427,052 | $13.08 | 50 |
| 2020 Q4 | 9,536,513 | $133,985,000 | +$6,730,351 | $14.05 | 39 |
| 2020 Q3 | 9,051,029 | $107,615,000 | +$107,615,000 | $11.89 | 28 |